BPC-157
Preclinical ResearchAlso known as: Body Protection Compound, PL 14736, Bepecin
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied in animal models for its potential roles in tissue repair, angiogenesis, and cytoprotection across multiple organ systems.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Muscle Recovery & Repair
- Skin & Wound Healing
- Tendon & Joint Health
- Gut & GI Health
Research suggests BPC-157 may act through growth hormone receptor pathways, nitric oxide system modulation, and promotion of angiogenesis via upregulation of VEGF. Animal studies indicate interactions with the dopaminergic and serotonergic systems.
Human safety data is limited. All published research is from animal models. No completed human clinical trials as of 2024.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- Pentadecapeptide BPC 157 and the central nervous system
Vukojević J et al. (2022). Neural Regeneration Research.DOI: 10.4103/1673-5374.320969
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review
Józwiak M et al. (2025). Pharmaceuticals.DOI: 10.3390/ph18020185
Want to learn more?
Ask Research Chat about BPC-157Half-Life
~4 hours (estimated from animal studies)
Administration
subcutaneous injection, oral (animal models)
Legal Status (US)
Research chemical in the US. Not approved for human use by the FDA.
112 indexed research passages
Related Peptides
Tropisetron is a 5-HT3 receptor antagonist and alpha7 nicotinic acetylcholine receptor agonist approved in various countries for chemotherapy-induced nausea. Research has also examined its potential roles in pain management, fibromyalgia, and cognitive enhancement through its dual receptor pharmacology.
KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its potent anti-inflammatory properties, particularly in gut epithelial models and inflammatory bowel disease research.
Larazotide is a synthetic octapeptide that acts as a tight junction regulator in gut epithelium. Research has examined its potential to reduce intestinal permeability ('leaky gut') in celiac disease and other inflammatory gut conditions by antagonizing the zonulin pathway.
LL-37 is the only known human cathelicidin antimicrobial peptide, derived from the C-terminal cleavage of hCAP18 and produced primarily by epithelial cells, neutrophils, and macrophages. Research has examined its roles in innate immune defense, wound healing, angiogenesis promotion, and modulation of inflammatory responses, as well as its potential as a therapeutic agent.